

CLIA# 45D2009077 1500 Interstate 35W Denton, TX 76207 Clinical Expert Line: 940-383-2223

Page 1 of 4

MOLECULAR PATHOLOGY REPORT

FACILITY INFORMATION

Facility Name: Facility Demo, LLC. Provider Name: PHYSICIAN DEMONSTRATION M.D.

NPI: 100000000 Address: 1500 Interstate 35 Denton, TX 76207 Phone: 940-383-2223

PATIENT INFORMATION Name: HTRXTEST, DEMO DOB: 01/12/1984

Gender: Female Address: 1234 AStreet Dr Denton, TX 79606, Taylor, US Phone: Race: Asian Ethnicity: Hispanic or Latino

SPECIMEN INFORMATION Lab Accession Number: 7941868 Date Collected: 08/04/2022

Date Received by Lab: 08/05/2022 Date Reported: 08/05/2022 Sample Type: Urinary Tract Infection Area of Interest: URINE SWAB Cross Reference #:

Microbial Load*

ary Tract Infect	tion Plus Pathogens Detect	ad		Results	Copies/mL*	*Approximate copies of targ nucleic acid per mL (Low: <100,000; Moderate:100,000-3.9 Million Hick: > 2.0 Million		
nary Tract Infection Plus Pathogens Detected				Results	copies/inc	High: >3.9Million)		
cterial Pathogens				Detected	320,000	Moderate		
terococcus spp (fae cherichia coli								
cherichia coli				Detected	13,000,000	High		
Quick Summary A (++): BEST ACTIV (+): GOOD ACTIV (±): VARIABLE AC	ITY	Enterococcus spp	Escherichia coli					
Penicillins	Ampicillin (IV/IM/po)	+	±					
	Amoxicillin (po)	+	±					
	Amoxicillin Clavulanic acid (po)	+	+					
Fluoroquinolones	Ciprofloxacin (po/OT/OP/IV)	±	+					
	Delafloxacin (po/IV)	+	+					
	Ofloxacin (po/OT/OP)	±	+					
	Levofloxacin (po/OP/IV)	+	+					
	Moxifloxacin (po/OP/IV)	+	+					
	Norfloxacin (po)	+	+					
	Gemifloxacin (po)	+	+					
Tetracyclines	Doxycycline (po/IV)	±	±					
	Minocycline (po/IV)	±	±					
	Omadacycline (po/IV)	+	+					
	Tetracycline (po)	±	±					
Nitrofuran	Nitrofurantoin (Macrobid) (po)	+	+					
Phosphidic acid derivative	Fosfomycin (po)	±	+					

Quick Summary Table above shows potentially effective oral antibiotic(s) for the above-noted bacteria (assumes mono-antimicrobial therapy, unless otherwise specified). Detected antimicrobial resistance gene(s) (as applicable) has(have) been integrated into antibiotic selection. Based on patient-specific clinical data, multi-antimicrobial therapy might be indicated in some cases (see Summary Antibiogram below).***

Comments:



DOB: 01/12/1984

Antimicrobial Resistance Genes Detected	Results
dfr (A1, A5), sul (1,2)	Detected
Potential resistance to Trimethoprim and/or Sulfamethoxazole.	

Escherichia coli

0 \pm \pm + + + + + + + + + + + + + + ++ + + + + + + + ++ + + + + +

PERSONALIZED SUMMARY ANTIBIOGRAM

Antibiotic Table Legend:

	Antibiotic Table Legend:				
sensi	tive.	f bacterial cultural isolates are			
(+): G sensi		of bacterial cultural isolates are			
(±): V	ARIABLE ACTIVITY, 50-7	0% of bacterial cultural isolates			
	ensitive. Ion-Recommended antimi	icrobial;			
	Personalized (patient sp t, are a correlation of det	ecific) data included in this	٩		
antim	icrobial resistance genes		ds s		
	nicrobial sensitivity data. Inistration Mode: po = or	al IV = intravenous IM =	Enterococcus spp		
intrar	nuscular, OP = ophthalm	ic, OT = otic.	S		
	e antibiotics might not be .pdr.net, www. drugs.con	available in the US (see n, or www.rxlist.com for current	tere		
inform	mation).		Б		
Penicillins		Penicillin G (IV/IM)	+		
		Ampicillin (IV/IM/po)	+		
		Amoxicillin (po)	+		
		Amoxicillin Clavulanic acid (po)			
		Ampicillin Sulbactam (IV/IM)			
		Piperacillin Tazobactam (IV)	+		
	Carbapenems	Doripenem (IV)	±		
		Ertapenem (IV/IM)			
		Imipenem (IV/IM)	±		
		Imipenem Cilastatin Relebactam (IV)	±		
		Meropenem (IV)	±		
		Meropenem Vaborbactam (IV)	±		
	Monobactam	Aztreonam (IV/IM)	0		
	Fluoroquinolones	Ciprofloxacin (po/OT/OP/IV)	±		
		Delafloxacin (po/IV)	+		
		Ofloxacin (po/OT/OP)	±		
		Levofloxacin (po/OP/IV)	+		
		Moxifloxacin (po/OP/IV)	+		
		Norfloxacin (po)	+		
		Gemifloxacin (po)	+		
		Gatifloxacin (OP)			
	Parenteral Cephalosporins	Cefazolin (IV/IM)	0		
	oopinaioopoinio	Cefotetan (IV/IM)			
		Cefoxitin (IV)			
		Cefuroxime (po/IV/IM)	0		
		Cefotaxime (IV/IM)			
		Ceftizoxime (IV/IM)			
		Ceftriaxone (IV/IM)			
		Ceftazidime (IV/IM)			
		Cefepime (IV/IM)			
		Ceftazidime Avibactam (IV)			
		Ceftaroline (IV)	0		
		Ceftobiprole (IV)	0		

		Enterococcus spp	:=
		cus	Escherichia coli
		Ö	i-
		terc	che
		Ш	ШŠ
	Ceftolozane Tazobactam (IV)	0	+
	Cefiderocol (IV)	0	+
Oral Cephalosporins	Cefadroxil (po)	0	±
	Cephalexin (po)	0	±
	Cefaclor (po)	0	±
	Cefprozil (po)	0	+
	Cefuroxime Axetil (po/IV/IM)	0	+
	Cefixime (po)	0	+
	Ceftibuten (po)	0	+
	Cefpodoxime (po)	0	+
A	Cefdinir (po)	0	+
Aminoglycosides	Gentamicin (IV/IM/OP)	±	+
	Tobramycin (IV/IM/OP)	0	+
	Amikacin (IV/IM) Plazomicin (IV)	0	+
Macrolides	Azithromycin (po/IV/OP)	0	+ ±
Tetracyclines	Doxycycline (po/IV)	±	±
l'eti acyclilles	Eravacycline (IV)	+	+
	Minocycline (po/IV)	±	+
	Omadacycline (po/IV)	+	+
	Tetracycline (po)	±	±
Glycylcycline	Tigecycline (IV)	+	+
Glycopeptides	Daptomycin (IV)	+	0
Lipopeptide Lipoglycopeptide	Vancomycin (po/IV/OP)	++	0
	Telavancin (IV)	+	0
	Oritavancin (IV)	+	0
	Dalbavancin (IV)	+	0
Oxazolidinones	Linezolid (po/IV)	+	0
	Tedizolid (po/IV)	+	0
Polymyxin Peptides	Polymyxin B (IV/IM/OP)	0	+
	Colistin (IV/IM/OT)	0	+
Peptidyl transferase inhibitor	Chloramphenicol (OP)	±	+
Nitrofuran	Nitrofurantoin (Macrobid) (po)	+	+



DOB: 01/12/1984

PERSONALIZED SUMMARY ANTIBIOGRAM

		Enterococcus spp	Escherichia coli	
Phosphidic acid derivative	Fosfomycin (IV)	±	+	
derivative	Fosfomycin (po)	±	+	
Streptogramin Combination	Quinupristin Dalfopristin (IV)	+	0	

TESTED ASSAY RESULTS

All tested microbe-related and resistance gene results (see below) are NOT DETECTED (NEGATIVE), unless indicated as DETECTED (POSITIVE), in above Detected Results Summary section.

Candida spp (albicans, glabrata, parapsilosis, tropicalis)	Morganella morganii
Trichomonas vaginalis	Streptococcus pyogenes (Group A strep)
Acinetobacter baumannii	Citrobacter freundii
Enterobacter spp (aerogenes, cloacae)	Enterococcus spp (faecalis, faecium)
Escherichia coli	Klebsiella spp (pneumoniae, oxytoca)
Mycoplasma spp (genitalium, hominis)	Proteus spp (mirabilis, vulgaris)
Pseudomonas aeruginosa	Serratia marcescens
Staphylococcus aureus	Staphylococcus spp (coagulase negative: epidermidis, haemolyticus, lugdunensis, saprophyticus)
Streptococcus agalactiae (Group B Strep)	Ureaplasma spp (urealyticum, parvum)
ACT, MIR, FOX, ACC Groups	SHV, KPC Groups
CTX-M1 (15), M2 (2), M9 (9), M8/25 Groups	IMP, NDM, VIM Groups
OXA-48, 51	qnr A2, B2
ermB, C; mefA	mecA
tet B, tet M	dfr (A1, A5), sul (1,2)
VanA, VanB	

Analyzed by: Carrie Wilks, PhD

Cani Wilk

Date: 08/05/2022 15:27



DOB: 01/12/1984



MEET WITH OUR CLINICAL EXPERTS

Real-Time polymerase chain reaction (TaqMan qPCR) was utilized for detection. Microbial sensitivity testing is not performed at this lab. Testing performed by AIT Laboratories (a HealthTrackRx Company; 1500 Interstate 35W, Denton TX 76207; CLIA# 45D2009077). This test was developed and its performance characteristics determined by American Institute of Toxicology, Inc. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

National Infectious Disease Consensus Data *Potentially effective oral antibiotics, based on presence of detected microbes, antimicrobial resistance genes, and national antimicrobial sensitivity data (see Summary Antibiogram).